论文部分内容阅读
目的:检测C-erbB-2和VEGF在乳腺癌中的表达并探讨其临床意义。方法:采用免疫组化SP法检测127例乳腺癌组织及40例良性乳腺疾病组织中C-erbB-2和VEGF的表达情况。结果:C-erbB-2和VEGF在乳腺癌组织中阳性表达率分别为47.2%和37.6%,与良性乳腺腺病组织比较,其差异有统计学意义(P<0.05);在127例乳腺癌患者中,随乳腺癌组织学分级的增高,C-erbB-2、VEGF阳性率表达也增高;有淋巴结转移及复发的患者其乳腺癌组织C-erbB-2和VEGF阳性表达率明显高于无淋巴结转移及复发的患者,差异有统计学意义(P<0.05);另外,有淋巴结转移及复发的患者,其乳腺癌组织C-erbB-2和VEGF的共同表达的阳性率明显高于无淋巴结转移及复发的患者(P<0.01)。结论:检测C-erbB-2、VEGF的表达对乳腺癌临床分级及预后的判断有一定意义。
Objective: To detect the expression of C-erbB-2 and VEGF in breast cancer and to explore its clinical significance. Methods: The expressions of C-erbB-2 and VEGF in 127 cases of breast cancer tissues and 40 cases of benign breast diseases were detected by immunohistochemical SP method. Results: The positive rates of C-erbB-2 and VEGF in breast cancer tissues were 47.2% and 37.6%, respectively, which were significantly different from those of benign breast adenosis (P <0.05). In 127 cases of breast cancer The positive rate of C-erbB-2 and VEGF was also increased with the histological grade of breast cancer. The positive rates of C-erbB-2 and VEGF in breast cancer tissues with lymph node metastasis and relapse were significantly higher than those without lymph node metastasis Lymph node metastasis and recurrence in patients with lymph node metastasis and recurrence, the difference was statistically significant (P <0.05); In addition, patients with lymph node metastasis and recurrence, the positive rate of co-expression of breast cancer C-erbB-2 and VEGF were significantly higher than those without lymph node Metastasis and recurrence of patients (P <0.01). Conclusion: Detecting the expression of C-erbB-2 and VEGF has certain significance in judging the clinical grade and prognosis of breast cancer.